Search

Displaying results 3071 - 3080 of 10000 in total
  1. Drug

    Avibactam

    go.drugbank.com/drugs/DB09060
    ApprovedInvestigational

    This combination was approved by the FDA on February 25, 2015 for the treatment of complicated intra-abdominal infections in combination with metronidazole, and the treatment of complicated urinary tract … Avibactam is a non-β-lactam β-lactamase inhibitor that is available in combination with ceftazidime (Avycaz).

  2. Drug

    Magnesium trisilicate

    go.drugbank.com/drugs/DB09281
    Approved

    Magnesium trisilicate is an inorganic compound that is used as an antacid in the treatment of peptic ulcers.

  3. Drug

    Oxalic Acid

    go.drugbank.com/drugs/DB03902
    Experimental

    A strong dicarboxylic acid occurring in many plants and vegetables. It is produced in the body by metabolism of glyoxylic acid or ascorbic acid. It is not metabolized but excreted in the urine. … It is used as an analytical reagent and general reducing agent. [PubChem]

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Pegsunercept

    go.drugbank.com/drugs/DB06611
    Investigational

    Phase II clinical trials were completed in January 2010.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Trastuzumab emtansine

    go.drugbank.com/drugs/DB05773
    ApprovedInvestigational

    Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent … Trastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic

  6. Drug

    C326

    go.drugbank.com/drugs/DB06017
    Experimental

    C326 is an investigational compound under investigation in clinical trial NCT00353756 (Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn's Disease) for the treatment … The drug is composed of an IL-6–binding trimer and a IgG-binding domain.

  7. Drug

    Guselkumab

    go.drugbank.com/drugs/DB11834
    ApprovedInvestigational

    In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in dermatological manifestations of psoriasis. … IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation [A20357].

    Products: TREMFYA SOLUTION FOR INJECTION IN PRE-FILLED PEN 100MG/ML, TREMFYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/1ML
  8. Drug

    Zidebactam

    go.drugbank.com/drugs/DB13090
    Approved

    Zidebactam is a diazabicyclooctane that acts both as a beta-lactamase inhibitor and as an antibacterial in its own right, selectively binding penicillin-binding protein 2. … [L63350] It is available only in fixed combination with [cefepime], which binds PBP3 and PBP1a/b.

  9. Drug

    Rapacuronium

    go.drugbank.com/drugs/DB04834
    ApprovedWithdrawn

    Rapacuronium was withdrawn in 2001 in many countries due to risk of fatal bronchospasm.

  10. Drug

    Benzoin resin

    go.drugbank.com/drugs/DB11222
    Approved

    skin abrasions as tincture of benzoin, or benzoin in a solution of alcohol. … While benzoin resin is used as a common ingredient in incense-making and perfumery, it is also used clinically as a mild antiseptic agent in over-the-counter products to clean sores, cuts, wounds, and

    Mixtures: Skin-E-dip Ont